Prescription Drug News and Research

RSS
Express Scripts report shows that new exchange plan enrollees spent less on medications in Q1 2015

Express Scripts report shows that new exchange plan enrollees spent less on medications in Q1 2015

New analysis looks at costly impact of new Hepatitis C treatments in California

New analysis looks at costly impact of new Hepatitis C treatments in California

Adding tamper resistant properties to medications can help curb prescription drug abuse

Adding tamper resistant properties to medications can help curb prescription drug abuse

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

New research could help reverse side effects of acetaminophen overdose

New research could help reverse side effects of acetaminophen overdose

Medicare prescription drug benefit did not save any money overall, say researchers

Medicare prescription drug benefit did not save any money overall, say researchers

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

FDA accepts Tris Pharma's Dyanavel XR NDA for review

FDA accepts Tris Pharma's Dyanavel XR NDA for review

MedVantx launches MedStart Formulary Connect program for health systems and ACOs

MedVantx launches MedStart Formulary Connect program for health systems and ACOs

Twin Cities Orthopedics joins Deterra partnership program to reduce prescription drug abuse and misuse

Twin Cities Orthopedics joins Deterra partnership program to reduce prescription drug abuse and misuse

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

APS announces recipients of prestigious achievement awards during annual scientific meeting

APS announces recipients of prestigious achievement awards during annual scientific meeting

PCMA releases new ad campaign to highlight lower-cost preferred pharmacy plans in Medicare

PCMA releases new ad campaign to highlight lower-cost preferred pharmacy plans in Medicare

New study shows 'alarming rise' in costs of MS drugs over last 20 years

New study shows 'alarming rise' in costs of MS drugs over last 20 years

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Oxycodone-related deaths drop 25% after implementation of Prescription Drug Monitoring Program

Oxycodone-related deaths drop 25% after implementation of Prescription Drug Monitoring Program

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Catamaran acquires Healthcare Solutions for $405 million

Catamaran acquires Healthcare Solutions for $405 million

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.